7月16日消息-环球医学据悉，武田制药（美国）就北美费森尤斯医疗及其若干附属公司采购和供应Omontys（peginesatide）针剂签订供应协议。Affymax的omontys是仅有的一种每月给药一次，且在美国可买到的主要用于治疗慢性肾病（CKD）患者透析所致贫血的红细胞刺激剂（ESA）。

这项至2013年4月结束的协议允许北美费森尤斯医疗机构购买Omontys并在美国中心的机构内部使用，并针对其需求量提供产品的折扣和回扣。北美费森尤斯医疗机构已表示，其最初的计划是在未来几周在美国超过100个透析中心使用本产品，然后根据经验，评估可其能扩大到其他中心的潜力。财务条款尚未披露。

“我们都很激动能与世界领先的透析供应商之一——北美费森尤斯医疗机构合作，提供一种新型的治疗慢性肾病透析所致贫血的治疗方案，”武田分管市场营销的副总Nicole Mowad-Nassar说。

“作为一家致力于开发肾脏疾病新疗法的生物技术公司， Affymax接受北美费森尤斯医疗机构的委托并进行改革，” Affymax首席执行官约翰Orwin说。“我们非常高兴地支持费森尤斯医疗把Omontys应用于其机构内部，并与他们一起进步。

Omontys是2012年03月27日由FDA批准，用于成人慢性肾病患者透析所致贫血的治疗药物。（环球医学）
 

原文

Takeda, Affymax announce supply agreement

      The agreement, which ends in April 2013, allows Fresenius Medical Care North America to purchase Omontys for use in US centers within its organization

      Singapore: Takeda Pharmaceuticals America has entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates. Omontys by Affymax is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population with chronic kidney disease (CKD) in the US.

       The agreement, which ends in April 2013, allows Fresenius Medical Care North America to purchase Omontys for use in US centers within its organization and provides for discounts and rebates on the product, subject to certain requirements. Fresenius Medical Care North America has stated that its initial plans are to adopt the product into more than 100 dialysis centers in the US over the next few weeks, and then, based on its experience, evaluate the potential to expand to additional centers. Financial terms were not disclosed.

      "We are excited to partner with Fresenius Medical Care North America, one of the world's leading dialysis providers, to offer a new therapeutic option for the treatment of anemia in its chronic kidney disease patients on dialysis," said Nicole Mowad-Nassar, vice president, marketing at Takeda.

      "As a biotechnology company dedicated to advancing new therapies for renal diseases, Affymax shares Fresenius Medical Care North America's commitment to innovation," stated John Orwin, chief executive officer of Affymax. "We are very pleased to support Fresenius Medical Care in these efforts to integrate Omontys into its organization and to collaborate with them moving forward."

       Omontys was approved by the FDA on March 27, 2012, for the treatment of anemia due to CKD in adult patients on dialysis.

      相关链接：http://www.biospectrumasia.com/biospectrum/news/2312/takeda-affymax-announce-supply-agreement

版权声明：本文系环球医学独家稿件，版权为环球医学所有。欢迎转载，请务必注明出处（环球医学网），否则必将追究法律责任。